Clinical study
A randomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis

https://doi.org/10.1016/0002-9343(87)90937-5Get rights and content

Abstract

Forty-seven climbers participated in a double-blind, randomized trial comparing acetazolamide 250 mg, dexamethasone 4 mg, and placebo every eight hours as prophylaxis for acute mountain sickness during rapid, active ascent of Mount Rainier (elevation 4,392 m). Forty-two subjects (89.4 percent) achieved the summit in an average of 34.5 hours after leaving sea level. At the summit or high point attained above base camp, the group taking dexamethasone reported less headache, tiredness, dizziness, nausea, clumsiness, and a greater sense of feeling refreshed (p ≤0.05). In addition, they reported fewer problems of runny nose and feeling cold, symptoms unrelated to acute mountain sickness. The acetazolamide group differed significantly (p ≤0.05) from other groups at low elevations (1,300 to 1,600 m), in that they experienced more feelings of nausea and tiredness, and they were less refreshed. These drug side effects probably obscured the previously established prophylactic effects of acetazolamide for acute mountain sickness. Separate analysis of an acetazolamide subgroup that did not experience side effects at low elevations revealed a prophylactic effect of acetazolamide similar in magnitude to the dexamethasone effect but lacking the euphoric effects of dexamethasone. This study demonstrates that prophylaxis with dexamethasone can reduce the symptoms associated with acute mountain sickness during active ascent and that acetazolamide can cause side effects that may limit its effectiveness as prophylaxis against the disease.

References (33)

  • CS Houston et al.

    Cerebral form of high altitude illness

    Lancet

    (1975)
  • RNW Wohns et al.

    Phenytoin and acute mountain sickness on Mount Everest

    Am J Med

    (1986)
  • I Singh et al.

    Acute mountain sickness

    N Engl J Med

    (1969)
  • PH Hackett et al.

    The incidence, importance, and prophylaxis of acute mountain sickness

    Lancet

    (1976)
  • CS Houston

    High altitude illness: disease with protean manifestations

    JAMA

    (1976)
  • HN Hultgren

    High altitude medical problems

    West J Med

    (1979)
  • J McLennan et al.

    Mountaineering accidents in the Sierra Nevada

    Am J Sports Med

    (1983)
  • DA Stamper et al.

    Evaluation of an acute mountain sickness questionnaire: effects of intermediate-altitude staging upon subjective symptomatology

    Avait Space Environ Med

    (1980)
  • EB Larson et al.

    Acute mountain sickness and acetazolamide: clinical efficacy and effect on ventilation

    JAMA

    (1982)
  • Acetazolamide in the control of acute mountain sickness

    Lancet

    (1981)
  • WO Evans et al.

    Amelioration of the symptoms of acute mountain sickness by staging and acetazolamide

    Avait Space Environ Med

    (1976)
  • GW Gray et al.

    Control of acute mountain sickness

    Aerospace Med

    (1971)
  • SA Forwand et al.

    Effect of acetazolamide on acute mountain sickness

    N Engl J Med

    (1968)
  • SM Cain et al.

    Low doses of acetazolamide to aid accommodation of men to altitude

    J Appl Physiol

    (1966)
  • TS Johnson et al.

    Prevention of acute mountain sickness by dexamethasone

    N Engl J Med

    (1984)
  • P Ferreira et al.

    Dexamethasone in the treatment of acute mountain sickness

    N Engl J Med

    (1985)
  • Cited by (105)

    • High-altitude illnesses: Old stories and new insights into the pathophysiology, treatment and prevention

      2021, Sports Medicine and Health Science
      Citation Excerpt :

      Finally, non-steroidal anti-inflammatory drugs like ibuprofen may represent an alternative or an add on to acetazolamide for AMS prevention.138 Dexamethasone is an efficient drug in preventing severe AMS, HACE, and HAPE.8,11,104,125,139 With regard to HACE, concerns have been raised whether dexamethasone treatment of severe and life-threatening HACE is still effective with preexisting dexamethasone prophylaxis and therefore represents a second-line strategy.

    • Efficacy of Acetazolamide for the Prophylaxis of Acute Mountain Sickness: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials

      2021, American Journal of the Medical Sciences
      Citation Excerpt :

      The PRISMA flow diagram of literature search was shown in Figure 1. The 22 selected trials comprised of 2019 participants with 1094 subjects receiving acetazolamide and 925 taking placebo.11,12,20-39 The proportions of males ranged from 49% to 100%, and the mean age ranged from 20.3 to 43.6 years.

    • Acute high-altitude pathologies and their treatment

      2020, Current Opinion in Endocrine and Metabolic Research
    • Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Acute Altitude Illness: 2019 Update

      2019, Wilderness and Environmental Medicine
      Citation Excerpt :

      Recommendation Grade: 1C. Although dexamethasone does not facilitate acclimatization like acetazolamide, prospective trials have established a benefit for dexamethasone in AMS prevention.28,29 The recommended adult doses are 2 mg every 6 h or 4 mg every 12 h. Very high doses (4 mg every 6 h) may be considered in very high-risk situations, such as military or search and rescue personnel being airlifted to altitudes >3500 m with immediate performance of physical activity, but should not be used except in these limited circumstances.

    View all citing articles on Scopus
    View full text